Trials / Recruiting
RecruitingNCT04949282
Spanish Series of Patients Treated With the Radionuclide Lutetium177
SEPTRALU, Spanish Series of Patients Treated With the Radionuclide Lutetium177
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,000 (estimated)
- Sponsor
- Sociedad Española de Medicina Nuclear e Imagen Molecular · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.
Detailed description
Patient data will be collected from medical records after obtaining consent and retrospectively.
Conditions
- Neuroendocrine Tumors
- Intestinal Neoplasms
- Pancreatic Neoplasms
- Stomach Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Nerve Tissue
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Neoplasms by Site
- Endocrine Gland Neoplasms
- Digestive System Diseases
- Gastrointestinal Disease
- Intestinal Diseases
- Pancreatic Disease
- Endocrine System Diseases
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lutetium [177Lu] oxodotreotide/dotatate | Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial) |
| DEVICE | Lutetium [177Lu] oxodotreotide/dotatate | Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial) |
Timeline
- Start date
- 2021-05-10
- Primary completion
- 2034-12-31
- Completion
- 2035-12-31
- First posted
- 2021-07-02
- Last updated
- 2022-12-23
Locations
20 sites across 1 country: Spain
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04949282. Inclusion in this directory is not an endorsement.